Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies.

Next Previous
Trial Profile

Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erlotinib (Primary) ; Temsirolimus (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Anal cancer; Breast cancer; Cholangiocarcinoma; Colon cancer; Gastric cancer; Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Periampullary cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thymoma; Thyroid cancer
  • Focus Adverse reactions

Most Recent Events

  • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
  • 19 Dec 2013 Planned end date changed from 1 Jan 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
  • 11 Jun 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top